Coldstream is proud to announce a collaboration with Goodwin Biotechnology, Inc. (GBI) for developing and manufacturing highly potent, cytotoxic biologics and bioconjucates (e.g., protein toxins, cytotoxic antibody drug conjugates, and other bioconjugates).
The area of potent bioconjugates has been growing for several years and due to the nature of the complexity of these molecules, the supply chain for developing these drugs can be quite challenging to manage. Coldstream views this relationship with GBI as an important step in helping to meet the needs of this industry. Coldstream will collaborate with GBI by leveraging GBI’s more than 10 years of bioconjugation experience to execute conjugation chemistry within Coldstream’s development and cGMP manufacturing facility. Together, GBI and Coldstream will bring their particular expertise to support the manufacture of these cytotoxic bioconjugates including analytical testing, formulation, and process development of liquid and lyophilized sterile highly-potent ADCs.
Goodwin Biotechnology is a world-class CMO that offers a Single Source Solution™ for our clients, by providing services from cell line development or exploratory proof of concept development through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and bioconjugates for early and late stage clinical trials as well as commercial manufacturing for cytotoxic Antibody Drug Conjugates (ADCs). With over 20 years of experience as an independent contract manufacturer, GBI has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies.
For more information on Coldstream’s experience click here
For more information on Goodwin’s bioconjugation experience click here